Ob/gyns are increasingly being called upon to manage subclinical thyroid disease. In this concluding article of a two-part series, two experts clarify the controversy over when to treat mild hyperthyroidism. Do treat a mildly overactive thyroid in elderly patients, they say, because low bone density and cardiac abnormalities can do substantial harm.
Few colleagues would argue over how to diagnose or treat overt thyroid disease. But it's a different story for more subtle "mild" thyroid disease-a term now commonly preferred to "subclinical."1 A key point from our article on mild hypothyroidism ("When should you screen for and treat mild hypothyroidism?" Contemporary OB/GYN, January 2006) http://www.contemporaryobgyn.net/obgyn/article/articleDetail.jsp?id=283482 holds true for mild hyperthyroidism: Diagnosing and deciding when to treat mild thyroid disease is still complicated by controversies over the reference values of the thyroid function tests upon which we base the diagnosis of disease and many clinical decisions. Once again our goal here is to discuss factors affecting your decision on when to treat mild hyperthyroidism and to give causes, guidelines, and treatment options.
Measuring 'normal' thyroid function
Also as discussed in Part I, when individuals with risk factors for autoimmune thyroid disease (especially thyroid antibodies), were excluded from a large control population, the average TSH was ~1.5 μU/mL.2 The lower limit for TSH in this group, and in other reports, was ~0.4 μU/mL. [Hence, mild hyperthyroidism may be defined by a TSH below 0.4 μU/mL with normal thyroid hormone levels (free T4 and T3). However, patients with mild hyperthyroidism are often divided further into two subgroups, one with a TSH of 0.1 to 0.4, and a second group with TSH under 0.1. With third-generation TSH assays, TSH may be reported at levels below 0.1, and this clearly indicates hyperthyroidism.]
Chemoattractants in fetal membranes enhance leukocyte migration near term pregnancy
November 22nd 2024A recent study highlights the release of chemoattractants from human fetal membranes at term, driving leukocyte activation and migration, with implications for labor and postpartum recovery.
Read More
Reproductive genetic carrier screening: A tool for reproductive decision-making
November 22nd 2024A new study highlights the efficacy of couple-based reproductive genetic carrier screening in improving reproductive decisions and outcomes, emphasizing its growing availability and acceptance among diverse populations.
Read More
Early preterm birth risk linked to low PlGF levels during pregnancy screening
November 20th 2024New research highlights that low levels of placental growth factor during mid-pregnancy screening can effectively predict early preterm birth, offering a potential tool to enhance maternal and infant health outcomes.
Read More